KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $921.4 million.

  • Sarepta Therapeutics' Total Current Liabilities rose 3172.83% to $921.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $921.4 million, marking a year-over-year increase of 3172.83%. This contributed to the annual value of $731.7 million for FY2024, which is 1193.67% up from last year.
  • Sarepta Therapeutics' Total Current Liabilities amounted to $921.4 million in Q3 2025, which was up 3172.83% from $919.9 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Total Current Liabilities ranged from a high of $921.4 million in Q3 2025 and a low of $364.7 million during Q1 2021
  • In the last 5 years, Sarepta Therapeutics' Total Current Liabilities had a median value of $602.9 million in 2022 and averaged $587.1 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 6144.79% in 2022, then tumbled by 2523.95% in 2023.
  • Sarepta Therapeutics' Total Current Liabilities (Quarter) stood at $452.7 million in 2021, then soared by 36.86% to $619.6 million in 2022, then increased by 5.5% to $653.7 million in 2023, then rose by 11.94% to $731.7 million in 2024, then rose by 25.93% to $921.4 million in 2025.
  • Its Total Current Liabilities stands at $921.4 million for Q3 2025, versus $919.9 million for Q2 2025 and $605.6 million for Q1 2025.